108 related articles for article (PubMed ID: 15905809)
1. Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma.
Miki I; Tamura T; Nakamura T; Makimoto H; Hamana N; Uchiyama H; Shirasaka D; Morita Y; Yamada H; Aoyama N; Sakaeda T; Okumura K; Kasuga M
Ther Drug Monit; 2005 Jun; 27(3):369-74. PubMed ID: 15905809
[TBL] [Abstract][Full Text] [Related]
2. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Nishiguchi K; Okuno T; Chayahara N; Miki I; Tamura T; Kadoyama K; Inokuma T; Takemoto Y; Nakamura T; Kataoka K; Sakaeda T
Int J Med Sci; 2010 Jan; 7(1):48-54. PubMed ID: 20151048
[TBL] [Abstract][Full Text] [Related]
3. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
4. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling.
Altinok A; Lévi F; Goldbeter A
Eur J Pharm Sci; 2009 Jan; 36(1):20-38. PubMed ID: 19041394
[TBL] [Abstract][Full Text] [Related]
5. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
Fleming GF; Schumm P; Friberg G; Ratain MJ; Njiaju UO; Schilsky RL
BMC Cancer; 2015 Feb; 15():69. PubMed ID: 25885822
[TBL] [Abstract][Full Text] [Related]
6. Association between circadian and chemotherapeutic cycle effects on plasma concentration of 5-fluorouracil and the clinical outcome following definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Kuwahara A; Kobuchi S; Tamura T
Oncol Lett; 2019 Jan; 17(1):668-675. PubMed ID: 30655815
[TBL] [Abstract][Full Text] [Related]
7. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
Sakaeda T; Yamamori M; Kuwahara A; Hiroe S; Nakamura T; Okumura K; Okuno T; Miki I; Chayahara N; Okamura N; Tamura T
Ther Drug Monit; 2008 Aug; 30(4):497-503. PubMed ID: 18641541
[TBL] [Abstract][Full Text] [Related]
8. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
Etienne MC; Chatelut E; Pivot X; Lavit M; Pujol A; Canal P; Milano G
Eur J Cancer; 1998 Jan; 34(1):92-7. PubMed ID: 9624244
[TBL] [Abstract][Full Text] [Related]
9. Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: a possible mechanism of chemotherapy-induced circadian rhythm disturbances.
Terazono H; Hamdan A; Matsunaga N; Hayasaka N; Kaji H; Egawa T; Makino K; Shigeyoshi Y; Koyanagi S; Ohdo S
Biochem Pharmacol; 2008 Apr; 75(8):1616-22. PubMed ID: 18329632
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
Ross P; Nicolson M; Cunningham D; Valle J; Seymour M; Harper P; Price T; Anderson H; Iveson T; Hickish T; Lofts F; Norman A
J Clin Oncol; 2002 Apr; 20(8):1996-2004. PubMed ID: 11956258
[TBL] [Abstract][Full Text] [Related]
12. Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil.
Poen JC; Collins HL; Niederhuber JE; Oberhelman HA; Vierra MA; Bastidas AJ; Young HS; Slosberg EA; Jeffrey BR; Longacre TA; Fisher GA; Goffinet DR
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):93-9. PubMed ID: 9422563
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
Price TJ; Ross PJ; Hickish T; Tait D; Norman AR; Ford HE; Middleton G; Sumpter K; Hill M; Oates J; Cunningham D
Clin Colorectal Cancer; 2004 Feb; 3(4):235-42. PubMed ID: 15025796
[TBL] [Abstract][Full Text] [Related]
14. No association of clock gene T3111C polymorphism and affective disorders.
Bailer U; Wiesegger G; Leisch F; Fuchs K; Leitner I; Letmaier M; Konstantinidis A; Stastny J; Sieghart W; Hornik K; Mitterauer B; Kasper S; Aschauer HN
Eur Neuropsychopharmacol; 2005 Jan; 15(1):51-5. PubMed ID: 15572273
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
17. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer.
Mehta VK; Poen JC; Ford JM; Oberhelman HA; Vierra MA; Bastidas AJ; Fisher GA
Am J Clin Oncol; 2001 Apr; 24(2):155-9. PubMed ID: 11319291
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.
Borro M; Botticelli A; Mazzuca F; Onesti EC; Gentile G; Romiti A; Cerbelli B; Mazzotti E; Marchetti L; Lionetto L; Simmaco M; Marchetti P
Oncotarget; 2017 Feb; 8(8):14050-14057. PubMed ID: 27738344
[TBL] [Abstract][Full Text] [Related]
20. Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.
Konings IR; Sleijfer S; Mathijssen RH; de Bruijn P; Ghobadi Moghaddam-Helmantel IM; van Dam LM; Wiemer EA; Verweij J; Loos WJ
Cancer Chemother Pharmacol; 2011 May; 67(5):1055-62. PubMed ID: 20652702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
